{"abstracts":[{"sha1":"85a3a8d33a1293da83f453fa0f5c12aa35ef5e91","content":"Lipoarabinomannan (LAM) is a major antigen of Mycobacterium tuberculosis (MTB). In this report, we evaluated the ability of a novel immunoassay to measure concentrations of LAM in sputum as a biomarker of bacterial load prior to and during treatment in pulmonary tuberculosis (TB) patients.","mimetype":"text/plain","lang":"en"},{"sha1":"efacd1f538bb00045dd8c6da9ccd232c0db35c64","content":"Phage display technology was used to isolate monoclonal antibodies binding to epitopes unique in LAM from MTB and slow-growing nontuberculous mycobacteria (NTM). Using these antibodies, a sandwich enzyme-linked immunosorbent assay (LAM-ELISA) was developed to quantitate LAM concentration. The LAM-ELISA had a lower limit of quantification of 15 pg/mL LAM, corresponding to 121 colony-forming units (CFUs)/mL of MTB strain H37Rv. It detected slow-growing NTMs but without cross-reacting to common oral bacteria. Two clinical studies were performed between the years 2013 and 2016 in Manila, Philippines, in patients without known human immunodeficiency virus (HIV) coinfection. In a case-control cohort diagnostic study, sputum specimens were collected from 308 patients (aged 17-69 years; 62% male) diagnosed as having pulmonary TB diseases or non-TB diseases, but who could expectorate sputum, and were then evaluated by smear microscopy, BACTEC MGIT 960 Mycobacterial Detection System (MGIT) and Lowenstein-Jensen (LJ) culture, and LAM-ELISA. Some sputum specimens were also examined by Xpert MTB/RIF. The LAM-ELISA detected all smear- and MTB-culture-positive samples (n = 70) and 50% (n = 29) of smear-negative but culture-positive samples (n = 58) (versus 79.3%; 46 positive cases by the Xpert MTB/RIF), but none from non-TB patients (n = 56). Among both LAM and MGIT MTB-culture-positive samples, log10-transformed LAM concentration and MGIT time to detection (TTD) showed a good inverse relationship (r = -0.803, p < 0.0001). In a prospective longitudinal cohort study, 40 drug-susceptible pulmonary TB patients (aged 18-69 years; 60% male) were enrolled during the first 56 days of the standard 4-drug therapy. Declines in sputum LAM concentrations correlated with increases of MGIT TTD in individual patients. There was a 1.29 log10 decrease of sputum LAM concentration, corresponding to an increase of 221 hours for MGIT TTD during the first 14 days of treatment, a treatment duration often used in early bactericidal activity (EBA) trials. Major limitations of this study include a relatively small number of patients, treatment duration up to only 56 days, lack of quantitative sputum culture CFU count data, and no examination of the correlation of sputum LAM to clinical cure.","mimetype":"text/plain","lang":"en"},{"sha1":"570b3604726d8171cd0d6fe1fb2175b07ddac89e","content":"These results indicate that the LAM-ELISA can determine LAM concentration in sputum, and sputum LAM measured by the assay may be used as a biomarker of bacterial load prior to and during TB treatment. Additional studies are needed to examine the predictive value of this novel biomarker on treatment outcomes.","mimetype":"text/plain","lang":"en"}],"refs":[{"index":0,"key":"ref1","year":2018,"container_name":"Global tuberculosis report","title":"Global tuberculosis report"},{"index":1,"extra":{"authors":["MG Ghany"],"doi":"10.1002/hep.22759","volume":"49"},"key":"ref2","year":2009,"container_name":"Hepatol Baltim Md","title":"American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update","locator":"1335"},{"index":2,"extra":{"authors":["S Wang"],"doi":"10.1016/j.biotechadv.2010.06.004","volume":"28"},"key":"ref3","year":2010,"container_name":"Biotechnol Adv","title":"Advances in developing HIV-1 viral load assays for resource-limited settings","locator":"770"},{"index":3,"extra":{"authors":["N Rockwood"],"doi":"10.1586/17476348.2016.1166960","volume":"10"},"key":"ref4","year":2016,"container_name":"Expert Rev Respir Med","title":"Assessment of treatment response in tuberculosis","locator":"643"},{"index":4,"extra":{"unstructured":"World Health Organization. Treatment of Tuberculosis: Guidelines [Internet]. 4th ed. 2010 [cited 2019 Mar 12]. Available: http://www.ncbi.nlm.nih.gov/books/NBK138748/"},"key":"ref5"},{"index":5,"key":"ref6","year":2016,"container_name":"WHO Treatment Guidelines for Drug-Resistant Tuberculosis","title":"WHO Treatment Guidelines for Drug-Resistant Tuberculosis"},{"index":6,"extra":{"authors":["RS Wallis"],"doi":"10.1016/s1473-3099(10)70003-7","volume":"10"},"key":"ref7","year":2010,"container_name":"Lancet Infect Dis","title":"Biomarkers for tuberculosis disease activity, cure, and relapse","locator":"68"},{"index":7,"extra":{"authors":["SW Hunter"],"volume":"261"},"key":"ref8","year":1986,"container_name":"J Biol Chem","title":"Structure and antigenicity of the phosphorylated lipopolysaccharide antigens from the leprosy and tubercle bacilli","locator":"12345"},{"index":8,"extra":{"authors":["SN Cho"],"doi":"10.3349/ymj.1990.31.4.333","volume":"31"},"key":"ref9","year":1990,"container_name":"Yonsei Med J","title":"Production of monoclonal antibodies to lipoarabinomannan-B and use in the detection of mycobacterial antigens in sputum","locator":"333"},{"index":9,"extra":{"authors":["E Sada"],"volume":"30"},"key":"ref10","year":1992,"container_name":"J Clin Microbiol","title":"Detection of lipoarabinomannan as a diagnostic test for tuberculosis","locator":"2415"},{"index":10,"extra":{"authors":["LM Pereira Arias-Bouda"],"volume":"38"},"key":"ref11","year":2000,"container_name":"J Clin Microbiol","title":"Development of antigen detection assay for diagnosis of tuberculosis using sputum samples","locator":"2278"},{"index":11,"extra":{"authors":["K Dheda"],"doi":"10.1371/journal.pone.0009848"},"key":"ref12","year":2010,"container_name":"PLoS ONE","title":"Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples","locator":"e9848"},{"index":12,"extra":{"authors":["JG Peter"],"doi":"10.5588/ijtld.11.0614","volume":"16"},"key":"ref13","year":2012,"container_name":"Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis","title":"Diagnostic accuracy of induced sputum LAM ELISA for tuberculosis diagnosis in sputum-scarce patients","locator":"1108"},{"index":13,"extra":{"authors":["D Chatterjee"],"doi":"10.1093/glycob/8.2.113"},"key":"ref14","year":1998,"container_name":"Glycobiology","title":"Mycobacterial lipoarabinomannan: an extraordinary lipoheteroglycan with profound physiological effects","locator":"113"},{"index":14,"extra":{"authors":["M Gilleron"],"doi":"10.1128/jb.187.3.854-861.2005","volume":"187"},"key":"ref15","year":2005,"container_name":"J Bacteriol","title":"Characterization of a truncated lipoarabinomannan from the Actinomycete Turicella otitidis","locator":"854"},{"index":15,"extra":{"authors":["KH Khoo"],"doi":"10.1074/jbc.270.21.12380","volume":"270"},"key":"ref16","year":1995,"container_name":"J Biol Chem","title":"Inositol phosphate capping of the nonreducing termini of lipoarabinomannan from rapidly growing strains of Mycobacterium","locator":"12380"},{"index":16,"extra":{"authors":["SK Angala"],"doi":"10.1038/nchembio.2571","volume":"14"},"key":"ref17","year":2018,"container_name":"Nat Chem Biol","title":"Covalent modifications of polysaccharides in mycobacteria","locator":"193"},{"index":17,"extra":{"authors":["CJ Petzold"],"doi":"10.1016/j.jasms.2005.02.023","volume":"16"},"key":"ref18","year":2005,"container_name":"J Am Soc Mass Spectrom","title":"Structural characterization of Lipoarabinomannans from Mycobacterium tuberculosis and Mycobacterium smegmatis by ESI mass spectrometry","locator":"1109"},{"index":18,"extra":{"authors":["SK Angala"],"doi":"10.1021/acschembio.6b01071","volume":"12"},"key":"ref19","year":2017,"container_name":"ACS Chem Biol","title":"Biosynthesis of the Methylthioxylose Capping Motif of Lipoarabinomannan in Mycobacterium tuberculosis","locator":"682"},{"index":19,"extra":{"authors":["CE Chan"],"doi":"10.1038/srep10281"},"key":"ref20","year":2015,"container_name":"Sci Rep","title":"The diagnostic targeting of a carbohydrate virulence factor from M.Tuberculosis","locator":"10281"},{"index":20,"extra":{"authors":["GB Sigal"],"doi":"10.1128/jcm.01338-18","volume":"56"},"key":"ref21","year":2018,"container_name":"J Clin Microbiol","title":"A Novel Sensitive Immunoassay Targeting the 5-Methylthio-d-Xylofuranose-Lipoarabinomannan Epitope Meets the WHO's Performance Target for Tuberculosis Diagnosis","locator":"e01338"},{"index":21,"extra":{"unstructured":"Clinical and Laboratory Standards Institute. EP12-A2: User Protocol for Evaluation of Qualitative Test Performance; Approved GuidelineāSecond Edition. 2008."},"key":"ref22"},{"index":22,"extra":{"authors":["CC Boehme"],"doi":"10.1056/nejmoa0907847","volume":"363"},"key":"ref23","year":2010,"container_name":"N Engl J Med","title":"Rapid molecular detection of tuberculosis and rifampin resistance","locator":"1005"},{"index":23,"extra":{"authors":["CC Boehme"],"doi":"10.1016/s0140-6736(11)60438-8","volume":"377"},"key":"ref24","year":2011,"container_name":"Lancet","title":"Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study","locator":"1495"},{"index":24,"key":"ref25","year":2013,"title":"Guidance for Industry: Pulmonary Tuberculosis: Developing Drugs for Treatment"},{"index":25,"key":"ref26","year":2013,"title":"Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections"},{"index":26,"extra":{"authors":["AH Diacon"],"doi":"10.1016/j.tube.2013.12.002","volume":"94"},"key":"ref27","year":2014,"container_name":"Tuberc Edinb Scotl","title":"Time to positivity in liquid culture predicts colony forming unit counts of Mycobacterium tuberculosis in sputum specimens","locator":"148"},{"index":27,"extra":{"authors":["CM Bark"],"doi":"10.5588/ijtld.13.0063","volume":"17"},"key":"ref28","year":2013,"container_name":"Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis","title":"Comparison of time to positive and colony counting in an early bactericidal activity study of anti-tuberculosis treatment","locator":"1448"},{"index":28,"extra":{"unstructured":"Minister of Health, Labour and Welfare. Japanese Pharmacopoeia, Sixteenth Edition. 2011."},"key":"ref29"},{"index":29,"extra":{"authors":["U Andreasson"],"doi":"10.3389/fneur.2015.00179"},"key":"ref30","year":2015,"container_name":"Front Neurol","title":"A Practical Guide to Immunoassay Method Validation","locator":"179"},{"index":30,"extra":{"unstructured":"World Health Organization. Toman's tuberculosis: case detection, treatment and monitoring [Internet]. 2nd edition. 2004 [cited 2019 Mar 12]. Available: http://apps.who.int/iris/bitstream/handle/10665/42701/9241546034.pdf?sequence=1"},"key":"ref31"},{"index":31,"extra":{"authors":["PC Hopewell"],"doi":"10.1016/s1473-3099(06)70628-4"},"key":"ref32","year":2006,"container_name":"Lancet Infect Dis","title":"International standards for tuberculosis care","locator":"710"},{"index":32,"extra":{"authors":["KP Fennelly"],"doi":"10.1164/rccm.201203-0444oc","volume":"186"},"key":"ref33","year":2012,"container_name":"Am J Respir Crit Care Med","title":"Variability of infectious aerosols produced during coughing by patients with pulmonary tuberculosis","locator":"450"},{"index":33,"extra":{"authors":["R Blakemore"],"doi":"10.1164/rccm.201103-0536oc","volume":"184"},"key":"ref34","year":2011,"container_name":"Am J Respir Crit Care Med","title":"A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay","locator":"1076"},{"index":34,"extra":{"authors":["RN van Zyl-Smit"],"doi":"10.1371/journal.pone.0028815"},"key":"ref35","year":2011,"container_name":"PLoS ONE","title":"Comparison of quantitative techniques including Xpert MTB/RIF to evaluate mycobacterial burden","locator":"e28815"},{"index":35,"extra":{"authors":["SO Friedrich"],"doi":"10.1016/s2213-2600(13)70119-x"},"key":"ref36","year":2013,"container_name":"Lancet Respir Med","title":"Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment","locator":"462"},{"index":36,"extra":{"authors":["TJ Hellyer"],"volume":"37"},"key":"ref37","year":1999,"container_name":"J Clin Microbiol","title":"Quantitative analysis of mRNA as a marker for viability of Mycobacterium tuberculosis","locator":"290"},{"index":37,"extra":{"authors":["L Li"],"doi":"10.1128/jcm.01526-09","volume":"48"},"key":"ref38","year":2010,"container_name":"J Clin Microbiol","title":"Sputum Mycobacterium tuberculosis mRNA as a marker of bacteriologic clearance in response to antituberculosis therapy","locator":"46"},{"index":38,"extra":{"authors":["I Honeyborne"],"doi":"10.1128/jcm.00547-11","volume":"49"},"key":"ref39","year":2011,"container_name":"J Clin Microbiol","title":"Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatment","locator":"3905"},{"index":39,"extra":{"authors":["R Bowness"],"doi":"10.1093/jac/dku415","volume":"70"},"key":"ref40","year":2015,"container_name":"J Antimicrob Chemother","title":"The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations","locator":"448"},{"index":40,"extra":{"authors":["DA Barr"],"doi":"10.1016/j.tube.2016.03.001","volume":"98"},"key":"ref41","year":2016,"container_name":"Tuberc Edinb Scotl","title":"Serial image analysis of Mycobacterium tuberculosis colony growth reveals a persistent subpopulation in sputum during treatment of pulmonary TB","locator":"110"},{"index":41,"extra":{"authors":["AH Diacon"],"doi":"10.5588/ijtld.10.0616","volume":"15"},"key":"ref42","year":2011,"container_name":"Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis","title":"Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients","locator":"949"},{"index":42,"extra":{"authors":["AH Diacon"],"doi":"10.1128/aac.02243-12","volume":"57"},"key":"ref43","year":2013,"container_name":"Antimicrob Agents Chemother","title":"Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis","locator":"2199"},{"index":43,"extra":{"unstructured":"Center for Drug Evaluation and Research, Food and Drug Administration. LOI Decision Letter for the Qualification of Lipoarabinomannan as a Pharmacodynamic/response Biomarker [Internet] [cited 2019 Mar 12]. Available from: https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/BiomarkerQualificationProgram/UCM608966.pdf"},"key":"ref44"}],"contribs":[{"index":0,"creator_id":"cquxnujzr5hxli5ingvhd4zski","raw_name":"Masanori Kawasaki","role":"author","extra":{"seq":"first"}},{"index":1,"raw_name":"Carmenchu Echiverri","role":"author"},{"index":2,"raw_name":"Lawrence Raymond","role":"author"},{"index":3,"raw_name":"Elizabeth Cadena","role":"author"},{"index":4,"raw_name":"Evelyn Reside","role":"author"},{"index":5,"raw_name":"Maria Tarcela Gler","role":"author"},{"index":6,"raw_name":"Tetsuya Oda","role":"author"},{"index":7,"raw_name":"Ryuta Ito","role":"author"},{"index":8,"raw_name":"Ryo Higashiyama","role":"author"},{"index":9,"raw_name":"Kiyonori Katsuragi","role":"author"},{"index":10,"raw_name":"Yongge Liu","role":"author"},{"raw_name":"Mark Hatherill","role":"editor","extra":{"seq":"first"}}],"license_slug":"CC-BY","language":"en","publisher":"Public Library of Science (PLoS)","pages":"e1002780","issue":"4","volume":"16","ext_ids":{"doi":"10.1371/journal.pmed.1002780","pmid":"30978194","pmcid":"PMC6461223"},"release_year":2019,"release_date":"2019-04-12","release_stage":"published","release_type":"article-journal","container_id":"iznnn644szdwva7khyxqzc73bi","webcaptures":[],"filesets":[],"files":[{"release_ids":["tjciijffzzh4lbrmieottdfqhm"],"mimetype":"application/pdf","urls":[{"url":"https://web.archive.org/web/20190503194556/https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1002780&type=printable","rel":"webarchive"},{"url":"https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1002780&type=printable","rel":"publisher"}],"sha256":"e1cf5f4706a2cc417d0f3220203e9afb0d80b1b6661c1ab205901c2709c091cb","sha1":"4b4f2f24e0b0c450f568549b16f3f982231d8c38","md5":"eb64d1c54695cb7290bbf7c0b998cfef","size":1513330,"extra":{"shadows":{"scimag_doi":"10.1371/journal.pmed.1002780","scimag_id":"75196147"}},"revision":"c389abfc-56cc-4e76-aed5-687fb466bb3a","ident":"otavsp4fnzhxbiudhckgbhwyyi","state":"active"}],"container":{"wikidata_qid":"Q1686921","issnp":"1549-1277","issne":"1549-1676","issnl":"1549-1277","publisher":"Public Library of Science","container_type":"journal","name":"PLoS Medicine","extra":{"abbrev":"PLoS Med.","country":"us","default_license":"CC-BY","doaj":{"archive":["PMC"],"as_of":"2022-07-06","default_license":"CC-BY","seal":true},"kbart":{"lockss":{"year_spans":[[2004,2009]]}},"languages":["en"],"publisher_type":"oa","road":{"as_of":"2018-01-24"},"sherpa_romeo":{"color":"green"},"urls":["https://journals.plos.org/plosmedicine/","http://www.plosmedicine.org/"]},"revision":"6511f755-9fb2-471e-8e54-f9dddcc83658","ident":"iznnn644szdwva7khyxqzc73bi","state":"active"},"work_id":"o3jn5du63fbujaj2fp3pxrk6tq","title":"Lipoarabinomannan in sputum to detect bacterial load and treatment response in patients with pulmonary tuberculosis: Analytic validation and evaluation in two cohorts","state":"active","ident":"tjciijffzzh4lbrmieottdfqhm","revision":"b2f091b7-dcb3-4843-8473-90cb1984077d","extra":{"crossref":{"license":[{"URL":"http://creativecommons.org/licenses/by/4.0/","content-version":"vor","delay-in-days":0,"start":"2019-04-12T00:00:00Z"}],"subject":["General Medicine"],"type":"journal-article"},"pubmed":{"pub_types":["Evaluation Study","Journal Article"]}}}